Rebecca Lee

14PUBLICATIONS
88CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 18, 2026
Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.

|May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

|Jan 19, 2026
Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019-2023 from the English systemic anti-cancer therapy national database.

Tommaso Bosetti, Oliver John Kennedy, Rebecca Lee

|Jan 19, 2026
Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations.

Sophia Kreft, Tommaso Bosetti, Rebecca Lee

|Aug 14, 2025
Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study.

Javier Pozas, Sowmya Cheruvu, Poorni Priya Jaganathan

|Jun 19, 2024
Why do patients with cancer die?

Adrienne Boire, Katy Burke, Thomas R Cox

Pageof 3

Frequent Collaborators

5 joint publications

Paul Lorigan

3 joint publications

Tommaso Bosetti

2 joint publications

Lasse H Jakobsen

2 joint publications

Oskar Wysocki